中國生物製藥(01177.HK):庫莫西利聯合氟維司羣治療內分泌經治的HR+/HER2-晚期乳腺癌III期研究數據將在2024 CSCO公佈
格隆匯8月29日丨中國生物製藥(01177.HK)宣佈,集團自主研發的創新藥「庫莫西利膠囊(TQB3616)」將於9月25日至29日舉行的全國臨牀腫瘤學大會暨2024年CSCO學術年會(2024 CSCO)公佈III期研究(TQB3616-III-01)最新成果,用於聯合氟維司羣治療內分泌經治的激素受體陽性╱人表皮生長因子受體2陰性(HR+/HER2-)晚期乳腺癌患者。
庫莫西利是一種新型週期蛋白依賴性激酶2、4和6(CDK2/4/6)抑制劑,對CDK2、CDK4、CDK6激酶有不同程度的抑制效果,並且對CDK4激酶具有較強的抑制能力[1]。研究結果顯示,庫莫西利對CDK2具有抑制作用,其增強的CDK2和CDK4抑制活性可能有助於在臨牀上克服目前CDK4/6抑制劑的耐藥性問題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.